InvestorsHub Logo
Followers 72
Posts 2623
Boards Moderated 0
Alias Born 03/01/2013

Re: None

Wednesday, 10/14/2020 10:39:09 AM

Wednesday, October 14, 2020 10:39:09 AM

Post# of 226
New Analyst Rating---Jeffries puts a $25 target and buyout of CGEN imminent

Compugen assumed with a Buy at Jefferies Jefferies analyst Chris Howerton assumed coverage of Compugen with a Buy rating with a price target of $25, up from the firm's previous target of $20. The company's lead assets, alphaPVRIG and alphaTIGIT, are novel anti-cancer/immune-checkpoint drugs with evidence that supports pathways for broad tumor types, suggesting each drug could become "Keytruda-like," Howerton tells investors.

Read more at:
https://thefly.com/n.php?id=3174816
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CGEN News